Literature DB >> 9591635

Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p.

J S Rader1, D S Gerhard, M J O'Sullivan, Y Li, L Li, H Liapis, P C Huettner.   

Abstract

We have shown previously that a significant number of invasive cervical cancers (ICC) have nonrandom chromosomal losses in 3p, 6p, 11q, 2q, 6q, and 19q, thereby suggesting that genes involved in the suppression of tumor development or progression are located in these regions. Cervical intraepithelial neoplasia (CIN) III is considered the precursor lesion for ICC of squamous type and occurs frequently with ICC of glandular type. In an effort to define which chromosomal losses are present in the precursor lesions, we identified CIN III lesions from 24 ICC treated by radical hysterectomy. Thirty-three CIN III associated with 22 squamous carcinomas and 2 adenocarcinomas were carefully microdissected from the paraffin-embedded sections. The whole genomic DNA from CIN III was amplified with short random primers. DNA from ICC, CIN III, and normal tissue was analyzed at the six chromosomal regions with polymorphic markers. Thirty-eight percent of hysterectomy specimens had loss of heterozygosity (LOH) in at least one of the CIN III lesions from each case. Loss occurred in 30% of cases in 3p14.1-12 (37% for associated ICC), 21% in 6p23 (33%), 14% in 2q33-37 (27%), 0 in 11q23.3 (33%), 4% in 19q13.4 (13%), and 0 in 6q21-23.3 (18%). These results suggest that mutations in 3p and 6p are important early in tumorigenesis, whereas 11q and 6q contain genes important later in tumor progression. Invasive and preinvasive cervical lesions appear to develop from multifocal genetic events since consistent losses do not occur within all precursor lesions in the same patient.

Entities:  

Mesh:

Year:  1998        PMID: 9591635     DOI: 10.1002/(sici)1098-2264(199805)22:1<57::aid-gcc8>3.0.co;2-6

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

Authors:  Colleen L Doçi; Tanmayi P Mankame; Alexander Langerman; Kelly R Ostler; Rajani Kanteti; Timothy Best; Kenan Onel; Lucy A Godley; Ravi Salgia; Mark W Lingen
Journal:  Int J Gynecol Pathol       Date:  2012-01       Impact factor: 2.762

2.  Allelic loss in human papillomavirus-positive and -negative vulvar squamous cell carcinomas.

Authors:  A P Pinto; M C Lin; G L Mutter; D Sun; L L Villa; C P Crum
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  Identification and functional analysis of NOL7 nuclear and nucleolar localization signals.

Authors:  Guolin Zhou; Colleen L Doçi; Mark W Lingen
Journal:  BMC Cell Biol       Date:  2010-09-27       Impact factor: 4.241

4.  The genomic and transcriptomic landscape of a HeLa cell line.

Authors:  Jonathan J M Landry; Paul Theodor Pyl; Tobias Rausch; Thomas Zichner; Manu M Tekkedil; Adrian M Stütz; Anna Jauch; Raeka S Aiyar; Gregoire Pau; Nicolas Delhomme; Julien Gagneur; Jan O Korbel; Wolfgang Huber; Lars M Steinmetz
Journal:  G3 (Bethesda)       Date:  2013-08-07       Impact factor: 3.154

5.  The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7.

Authors:  Tanmayi P Mankame; Mark W Lingen
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

6.  HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia.

Authors:  Mariska Bierkens; Saskia M Wilting; Wessel N van Wieringen; Mark A van de Wiel; Bauke Ylstra; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  BMC Cancer       Date:  2012-01-24       Impact factor: 4.430

7.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.